Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasm, Residual 1Lymphoproliferative Disorders 1Lymphomatoid Granulomatosis 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Hairy Cell 1Leukemia 1Epstein-Barr Virus Infections 1

Interventions

Rituximab 12Tacrolimus 11Peripheral Blood Stem Cell Transplantation 10Mycophenolic Acid 9fludarabine phosphate 8Cyclophosphamide 8Whole-Body Irradiation 6Methotrexate 5Cyclosporine 5Antilymphocyte Serum 5Vemurafenib 4Methylprednisolone 4Cladribine 4Busulfan 4merphos 3Therapeutics 3Radiotherapy 3Alemtuzumab 3obinutuzumab 2ibrutinib 2fludarabine 2binimetinib 2aldesleukin 2Transplantation 2Specimen Handling 2Prednisone 2Melphalan 2Lenalidomide 2Interferon-alpha 2Filgrastim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Hairy Cell × Caves × Clear all
NCT00923013 2025-08-08

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
175 enrolled 16 charts
Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡